3SBio has been growing earnings at an average annual rate of 32.3%, while the Biotechs industry saw earnings growing at 36.2% annually. Revenues have been growing at an average rate of 17.8% per year. 3SBio's return on equity is 29.9%, and it has net margins of 47.9%.
Key information
32.27%
Earnings growth rate
33.33%
EPS growth rate
Biotechs Industry Growth
17.04%
Revenue growth rate
17.81%
Return on equity
29.89%
Net Margin
47.93%
Last Earnings Update
31 Dec 2025
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How 3SBio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
OTCPK:TRSB.F Revenue, expenses and earnings (CNY Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Dec 25
17,696
8,482
4,282
1,520
30 Sep 25
13,385
5,420
4,120
1,459
30 Jun 25
9,074
2,359
3,957
1,398
31 Mar 25
9,091
2,224
3,905
1,362
31 Dec 24
9,108
2,090
3,853
1,327
30 Sep 24
8,765
1,874
3,773
1,145
30 Jun 24
8,422
1,659
3,693
964
31 Mar 24
8,119
1,604
3,590
880
31 Dec 23
7,816
1,549
3,487
795
30 Sep 23
7,686
1,739
3,351
750
30 Jun 23
7,555
1,929
3,215
706
31 Mar 23
7,210
1,923
3,094
700
31 Dec 22
6,866
1,916
2,974
694
30 Sep 22
6,618
1,817
2,849
699
30 Jun 22
6,369
1,719
2,725
703
31 Mar 22
6,376
1,685
2,710
729
31 Dec 21
6,382
1,651
2,696
754
30 Sep 21
6,191
1,342
2,688
717
30 Jun 21
6,000
1,032
2,681
681
31 Mar 21
5,794
934
2,577
636
31 Dec 20
5,588
836
2,472
590
30 Sep 20
5,479
1,095
2,535
581
30 Jun 20
5,370
1,355
2,598
571
31 Mar 20
5,344
1,164
2,612
549
31 Dec 19
5,318
974
2,627
527
30 Sep 19
5,185
1,029
2,409
549
30 Jun 19
5,053
1,084
2,190
572
31 Mar 19
4,818
1,181
2,099
468
31 Dec 18
4,584
1,277
2,008
363
30 Sep 18
4,393
1,167
1,911
181
30 Jun 18
4,202
1,057
1,814
0
31 Mar 18
3,968
996
1,731
0
31 Dec 17
3,734
935
1,648
0
30 Sep 17
3,467
877
1,601
0
30 Jun 17
3,199
818
1,555
0
31 Mar 17
2,998
766
1,437
0
31 Dec 16
2,797
713
1,318
0
30 Sep 16
2,492
642
1,104
0
30 Jun 16
2,188
571
889
0
31 Mar 16
1,930
548
800
0
31 Dec 15
1,673
526
710
0
30 Sep 15
1,503
456
676
0
Quality Earnings: TRSB.F has high quality earnings.
Growing Profit Margin: TRSB.F's current net profit margins (47.9%) are higher than last year (23%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TRSB.F's earnings have grown significantly by 32.3% per year over the past 5 years.
Accelerating Growth: TRSB.F's earnings growth over the past year (305.8%) exceeds its 5-year average (32.3% per year).
Earnings vs Industry: TRSB.F earnings growth over the past year (305.8%) exceeded the Biotechs industry 54.5%.
Return on Equity
High ROE: TRSB.F's Return on Equity (29.9%) is considered high.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/07/07 11:23
End of Day Share Price
2026/06/26 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
3SBio Inc. is covered by 37 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.